



J.P. Morgan Healthcare

Conference

January 9, 2017

Jeffrey Leiden, M.D., Ph.D.

Chairman, President and Chief Executive Officer

Safe Harbor Statement

This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, (i) information pertaining to KALYDECO and ORKAMBI and the ongoing discovery, development and commercialization of Vertex's product candidates, (ii) information provided in the section captioned "Financial Profile," including preliminary financial information for the year ended December 31, 2016 and guidance for 2017 and (iii) the timing and outcome of regulatory applications, including MAAs. While the Company believes that these forward-looking statements are accurate, these statements are subject to risks and uncertainties that could cause actual outcomes to differ materially from the Company's current expectations. These risks and uncertainties include, among other things, that the Company's 2016 financial results are preliminary and subject to adjustment, that the company's expectations regarding its 2017 revenues and expenses may be incorrect (including because one or more of the company's assumptions underlying its expectations may not be realized), risks related to commercialization of and reimbursement for KALYDECO and ORKAMBI, the risk that data from the Company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and the risks and uncertainties listed in the Company's October 25, 2016 press release and under Risk Factors in the Company's 10-K and other filings with the SEC.



Key 2016 Milestones and Goals

	2016	 2017
	ORKAMBI approval and launch for ages 6-11 in the U.S.	
CYSTIC FIBROSIS	Long-term rate of lung function decline data for ORKAMBI	
	Phase 2 development for one or more next-generation correctors	
	Approval for KALYDECO in residual function mutations	
FINANCIAL	Total CF product revenues of \$1.68B, up from \$983M in 2015	
	KALYDECO guidance of \$670 - \$690M	
	ORKAMBI guidance of \$1.0 - \$1.1B	
	Year-end cash balance of \$1.43B	
PIPELINE	Bolster the CF and non-CF pipeline with internal and external assets	
		Advance one or more compounds from research into clinical development

Growing Our Business in 2017 and Beyond









Growing Our Business in 2017 and Beyond








Research Productivity and Strategy *Discovering and Developing Medicines to Treat Other Serious Diseases*



Cystic Fibrosis


- Rare, life-shortening, inherited disease caused by recessive mutations in the *CFTR* gene
- 75,000 people in North America, Europe and Australia
- Results in thick sticky mucus that obstructs the airways, intestine & ducts of the pancreas
- Median age at death in 2015 was 30 years
- Prior to 2012, treatments only addressed symptoms, not underlying cause of disease



AGE AT DEATH IN 2015



Goal: Carrier-like Benefits for All Patients Early in Life




CFTR2 Database. https://cftr2.org/. Accessed October 2016. Riordan JR, et al. *Science*. 1989;245:1066-73; Accurso FJ, et al. *J Cyst Fibros*. 2014;13:139-47;

Boyle MP, et al. Lancet Respir Med. 2014;2:527-38; Ramsey BW, et al. N Engl J Med. 2011;365:1663-72.


Long-Term Real-World Data for KALYDECO

Interim data from long-term observational safety study using U.S. and UK CF Registries Presented at NACFC



Provided as Percent Reduction with corresponding Risk Ratio (95% CI); *Not Statistically Significant Average KALYDECO exposure: 2.0 years in U.S. registry and 1.3 years in UK registry; Potential for confounding cannot be excluded but was partially addressed through matching and stratification


Biological Understanding of CF Provides Path to Develop Medicines for All Patients



Vertex CF Pipeline

RESEARCH	PHASE 1	PHASE 2	PHASE 3	APPROVED
CRISPR-Cas9 mRNA Small Molecules	VX-659 VX-445	VX-440, VX-152 VX-371	tezacaftor (VX-661)	ORKAMBI® KALYDECO®
 RESEARCH CRISPR/Cas9 Gene editing research collaboration mRNA Research collaboration and licensing agreement to develop mRNA Therapeutics™ Small Molecules Additional next-gen correctors potentially increasing benefit 	 PHASE 1 Next-Generation Correctors: Phase 1 study of VX-659 ongoing Phase 1 study of VX-445 planned for Q1 2017 	PHASE 2 Next-Generation Correctors: • Phase 2 studies of VX-440 and VX-152 ongoing ENAC: • Phase 2 study of VX-371 in combination with ORKAMBI ongoing	 PHASE 3 Ongoing broad Phase 3 program Key role in development of triple combination regimen 	APPROVED • First medicines to treat the cause of CF for people with specific mutations in the CFTR gene
			©2017 \	/ertex Pharmaceuticals Incorporated

Path to Treating All Patients





~25,000 Patients Eligible for Treatment with ORKAMBI in US, Europe, Australia and Canada

Initiated ORKAMBI Not Initiated ORKAMBI

~9,000 Patients


~16,000 Patients



~13,000 Patients Outside the U.S., Primarily Those Awaiting Formal Reimbursement Approvals



Path to Treating All Patients



Increasing the Number of Eligible Patients ORKAMBI and KALYDECO



Potential to treat ~10,000 additional children <12 years of age (ages <6 U.S. and <12 Europe) Data from Phase 3 efficacy and safety study to (lumacaftor/ivacaftor) support potential MAA approval in ages 6-11 200 mg / 125 mg tablets Phase 3 study in children ages 2-5 ongoing Potential to treat ~5,000 additional people with residual function mutations and also children <2 years of age Phase 3 study in infants ages 0-2 ongoing (ivacattor) oral granules 50.75 mg Continue to pursue FDA approval for certain residual function mutations

Label expansions could increase eligible patients from 29,000 to 44,000



Tezacaftor (VX-661) + Ivacaftor *Broad Phase 3 Development Program*



KEY GOALS

1

Evaluate the potential for a treatment option with an enhanced benefit/risk profile for patients with two copies of the F508del mutation

2

Evaluate the potential to **enhance benefit of KALYDECO monotherapy** in patients with one copy of the F508del mutation and a second mutation likely to respond to ivacaftor


3

Play a key role in development of **triple combination** regimens with a next-generation corrector Phase 3 Program Generates Safety and Efficacy Data in 1,000+ Patients

First Data Expected in First Half of 2017; NDA Planned Second Half of 2017




Path to Treating All Patients



16

High Maximal In Vitro Efficacy for Multiple Next-Generation Correctors






Broad Portfolio of Next-Generation Correctors


Correctors





18

Path to Treating All Patients



Genetic Approaches to Treat CF





CRISPR Collaboration

- Four-year research collaboration
- Initial focus:
 - Cystic Fibrosis
 - Sickle Cell Disease/Hemoglobinopathy
- Deal provides for option for exclusive licenses for up to 6 gene-based treatments

Moderna Collaboration

- Three-year research collaboration
- Focused on the use of mRNA therapies to treat the underlying cause of CF
 - Enable cells in the lungs to produce functional copies of the CFTR protein



messenger therapeutics

Growing Our Business in 2017 and Beyond

Cystic Fibrosis Developing Medicines to Treat Potentially All People with the Disease







Continued Revenue Growth with Launch of ORKAMBI

GLOBAL PRODUCT REVENUES ORKAMBI ~\$1.68B >70% **KALYDECO GROWTH** \$979M \$983M >110% **GROWTH** \$351M \$703M \$632M \$464M \$371M 2013 2016 2014 2015




Key 2016 Financial Metrics and 2017 Guidance

	2015	2016 Preliminary Results*	2017 Guidance
ORKAMBI Revenues	\$351M	\$979M	\$1.1 – \$1.3B
KALYDECO Revenues	\$632M	\$703M	\$690 - \$710M
Total CF Revenues	\$983M	\$1.68B	\$1.79 - \$2.01B
Non-GAAP Combined R&D and SG&A Expense	\$1.06B	\$1.21B	\$1.25 - \$1.30B
GAAP Combined R&D and SG&A Expense	\$1.37B	\$1.48B	TBA
Cash, cash equivalents & marketable securities (year-end)	\$1.04B	\$1.43B	N/A

An explanation of our Non-GAAP financial measures and reconciliation of our preliminary Non-GAAP combined R&D and SG&A expense is included in our January 8, 2017 press release. * The 2016 preliminary financial results are unaudited and are provided as approximations in advance of the company's complete financial results announcement on January 25, 2017.

CF Expansion Drives Sustainable Revenue and Earnings Growth & Enables Investment in Pipeline Assets





Growing Our Business in 2017 and Beyond

Cystic Fibrosis Developing Medicines to Treat Potentially All People with the Disease







Learnings in CF Have Transformed Our Investments in Early Research

Vertex invests in scientific innovation to create transformative medicines for specialty diseases.

RESEARCH PRINCIPLES

- Focus on validated targets that address causal human biology
- Create lab assays and clinical biomarkers to predict clinical response
- Discover and develop medicines that offer transformative benefit
- Identify rapid path to registration and beyond

DISEASES CURRENTLY BEING TARGETED IN VERTEX RESEARCH

Adrenoleukodystrophy (ALD) Alpha-1 Antitrypsin Deficiency (AATD) Sickle Cell Disease & Beta Thalassemia Polycystic Kidney Disease

Alpha-1 Antitrypsin Deficiency (AATD)

DISEASE

- Genetic disorder caused by a single point mutation in the SERPINA1 gene that causes a protein folding defect
- Causes lung & liver disease; 60,000 patients in the U.S.

CURRENT TREATMENT

- 10,000 patients currently treated
- Current replacement therapy only partially effective

CONSISTENT WITH VERTEX STRATEGY

- ✓ Validated target
- ✓ Predictive lab assays
- ✓ Potential for transformative benefit
- ✓ Rapid proof of concept





Key 2017 Milestones and Goals

	2016		2017
CYSTIC FIBROSIS	ORKAMBI approval and launch for ages 6-11 in the U.S.	\bigcirc	Phase 3 tezacaftor/ivacaftor data in multiple mutations (1H17)
	Long-term rate of lung function decline data for ORKAMBI	\bigcirc	Phase 2 proof-of-concept data for two triple combination regimens in CF patients (2H17)
	Phase 2 development for one or more next-generation correctors	\bigcirc	Phase 1 data for for VX-659 triple combination in CF patients (2H17)
		\bigcirc	Clinical development of a 4 th next-generation corrector (Q117)
	Total CF product revenues of \$1.68B, up from \$983M in 2015	\bigcirc	Total CF revenues of \$1.79 - \$2.01B
FINANCIAL	KALYDECO guidance of \$670 - \$690M	\bigcirc	Obtain reimbursement for ORKAMBI in multiple countries outside the U.S.
		\bigcirc	Non-GAAP combined R&D and SG&A expenses of \$1.25 - \$1.3B
	Year-end cash balance of \$1.43B		
PIPELINE	Bolster the CF and non-CF pipeline with internal and external assets	\bigcirc	Bolster the CF and non-CF pipeline with internal and external assets
		\bigcirc	Advance one or more compounds from research into clinical development





J.P. Morgan Healthcare Conference

January 9, 2017

Jeffrey Leiden, M.D., Ph.D.

Chairman, President and Chief Executive Officer